Debiopharm to Showcase Research Results of Their First-in-class Anti-staphylococcal Program at IDWeek 2024 in Los Angeles.

Debiopharm, a Swiss biopharmaceutical company, presented research results on their anti-staphylococcal program at IDWeek 2024 in Los Angeles. The program focuses on treating bone and joint infections caused by Staphylococcus aureus, a common bacterium known for antibiotic resistance. The company aims to address unmet medical needs in oncology and bacterial infections by developing innovative therapies. The research findings were presented by Dr. Alireza Shamaei-Tousi, highlighting the potential of their antibiotic program in treating challenging bacterial infections. [Extracted from the article]